3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
10
Carcinoma, Renal Cell
9
Kidney Neoplasms
7
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Leukemia
6
Lymphoma
5
Multiple Myeloma
4
Lymphoma, Follicular
4
Lymphoma, Mantle-Cell
3
Rectal Neoplasms
2
Neoplasms, Plasma Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neoplasms
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Standard of Care
2
tocilizumab
1
selinexor
1
lenzilumab
1
cilgavimab and tixagevimab drug combination
1
Practice Guidelines as Topic
1
Observation
1
Interferon-alpha
1
Immunoglobulin G
1
IMM-101
1
Disulfides
1
CVnCoV COVID-19 vaccine
1
COVID-19 Vaccines
1
BNT162 Vaccine
1
Atorvastatin
1
2019-nCoV Vaccine mRNA-1273
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
COVID-19
×
Interferon-alpha
×
Clear all
NCT04534725
2023-08-24
C-SMART
Peter MacCallum Cancer Centre, Australia
Phase 3
Completed
441 enrolled